Menu
Search
|

Menu

Close
X

Beigene Ltd BGNE.OQ (NASDAQ Stock Exchange Global Select Market)

133.12 USD
+1.11 (+0.84%)
As of 4:00 PM EDT
Previous Close 132.01
Open 132.01
Volume 68,159
3m Avg Volume 99,629
Today’s High 134.70
Today’s Low 132.00
52 Week High 179.00
52 Week Low 105.19
Shares Outstanding (mil) 3.26
Market Capitalization (mil) 4,400.80
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.57 Mean rating from 14 analysts

KEY STATS

Revenue (mm, USD)
FY19
321
FY18
198
FY17
238
FY16
1
EPS (USD)
FY19
-0.326
FY18
-0.921
FY17
-0.183
FY16
-0.274
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.66
Price to Sales (TTM)
vs sector
--
7.91
Price to Book (MRQ)
vs sector
16.21
5.38
Price to Cash Flow (TTM)
vs sector
--
24.36
Total Debt to Equity (MRQ)
vs sector
59.72
14.55
LT Debt to Equity (MRQ)
vs sector
59.72
10.20
Return on Investment (TTM)
vs sector
-57.59
14.48
Return on Equity (TTM)
vs sector
-77.45
15.78

EXECUTIVE LEADERSHIP

John Oyler
Executive Chairman of the Board, Chief Executive Officer, Since 2010
Salary: $97,664.00
Bonus: $1,272,070.00
Xiaobin Wu
General Manager, China and President, Since 2018
Salary: --
Bonus: --
Howard Liang
Chief Financial Officer and Chief Strategy Officer, Since 2015
Salary: --
Bonus: --
Eric Hedrick
Interim Chief Medical Officer, Immuno-Oncology, Since 2019
Salary: --
Bonus: --
Jane Huang
Chief Medical Officer, Hematology, Since 2016
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

C/O Mourant Governance Services
94 Solaris Avenue, Camana Bay
GRAND CAYMAN     KY1-1108

Phone: +1345.9494123
Site:

BeiGene, Ltd. is principally engaged in biopharmaceutical business. The Company is mainly engaged in the research and development, production and sales of innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer. The Company's main products include Zanubrutinib (BGB-3111), Tislelizumab (BGB-A317) and Pamiparib (BGB-290).

SPONSORED STORIES